Newsletter

006280 - GC Biopharma Corp.

006280 Summary
Biopharma
Stock Price & Overview
₩127,600 +600 (+0.47%) Close · Sep 4, 2026 KST
KOSPI | ₩KRW | Close: ₩127,600  ≈ US$91  ·  Market cap ₩1.5tn (≈ $1.1bn)
What kstock news is. Short items on what actually happened — a filing, an order, a buyback, a result — written from the Korean filing or the Korean press for people who cannot read either. Each one puts the event against a figure from this company's own statements. No view, no rating; that is what analysis is for.

006280 News

All kstock news »
ks

GC Biopharma Corp. Receives Korean Approval for Flu Vaccine Trial - Newsis

GC Biopharma Corp. (006280) received Korean approval for a phase 2/3 trial of its GC3114B flu vaccine.

kstock NewsToday, 7:19 PM
1 item. Written from DART filings and Korean press reports; every item lists its source.

Similar to 006280

SymbolLast Price
140410Mezzion Pharma Co., Ltd.₩65,000
+0.0%
068760Celltrion Pharm, Inc.₩40,850
+0.0%
007390Naturecell Co., Ltd.₩23,950
+0.2%
950160Kolon Tissue Gene, Inc.₩17,100
+1.1%
039200Oscotec, Inc.₩36,600
+1.9%
069620Daewoong Pharma₩116,100
+1.1%
290650L & C BIO Co., Ltd.₩47,900
-1.4%
127120JS Link₩33,600
+12.4%
475830Orum Therapeutics, Inc.₩55,900
+2.6%
195940HK inno.N Corporation₩42,050
+0.7%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.